Results 151 to 160 of about 66,826 (280)

Tubulointerstitial nephritis and uveitis syndrome in children: What to keep an eye on

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose The purpose of this study was to determine the disease course in patients with tubulointerstitial nephritis and uveitis (TINU) syndrome, focusing on long‐term outcome and the incidence of complications such as chronic kidney disease (CKD).
Jytte Hendrikse   +4 more
wiley   +1 more source

Adalimumab-responsive Monogenic Inflammatory Bowel Disease With Pseudopolyposis Characteristic of <i>TGFBR2</i> Variant in Loeys-Dietz Syndrome. [PDF]

open access: yesDEN Open
ABSTRACT Loeys‐Dietz syndrome (LDS) is an autosomal dominant connective tissue disorder caused by pathogenic variants in TGFBR1 or TGFBR2. It is characterized by vascular fragility, skeletal abnormalities, and predisposition to allergic and inflammatory conditions, including monogenic inflammatory bowel disease (IBD).
Sado T   +9 more
europepmc   +2 more sources

Investigating the Effect of Tumour Necrosis Factor Antagonist on Olfaction

open access: yesClinical Otolaryngology, EarlyView.
ABSTRACT Objectives Tumour Necrosis factor antagonists is a potent anti‐inflammatory medication and has shown to improve olfactory function in murine models. The primary aim was to determine the effect of TNF antagonists on olfactory performance in humans.
Andreas Espehana   +7 more
wiley   +1 more source

Biosimilars in Adult and Pediatric Noninfectious Uveitis. [PDF]

open access: yesClin Ophthalmol
Ploeger CG   +3 more
europepmc   +1 more source

Economic burden of hidradenitis suppurativa based on healthcare resource utilization: German claims data analysis

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease affecting approximately 0.1% of the German population. Patients with HS require substantial healthcare resource utilization. This study aimed to assess the economic burden associated with HS in Germany.
Falk G. Bechara   +7 more
wiley   +1 more source

Comparing the pharmacokinetics of adalimumab originator and biosimilar product in patients with Inflammatory bowel disease or autoimmune disease. [PDF]

open access: yesSaudi Pharm J
Drweesh H   +14 more
europepmc   +1 more source

Managing Monitoring: Biologic Therapy for Psoriasis

open access: yes
JEADV Clinical Practice, EarlyView.
Claudine Howard‐James   +1 more
wiley   +1 more source

Cutaneous non‐tuberculous mycobacterial infections: A retrospective study of 94 cases from Germany

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background Cutaneous non‐tuberculous mycobacterial infections (NTM) remain a diagnostic and therapeutic challenge. The aim of this study was to characterize cutaneous NTM infections in Germany over a 24‐year‐period. Patients and Methods 73 patients with cutaneous NTM infections diagnosed at 17 different German University Hospitals from 2000 ...
Luisa Bopp   +6 more
wiley   +1 more source

Roadmap for the accelerated development and clinical translation of fluorescent tracers: Adalimumab-680LT as a proof of concept. [PDF]

open access: yesInt J Pharm X
Huizinga HK   +8 more
europepmc   +1 more source

Inconsistent standard of care for tuberculosis screening and preventive therapy before initiating systemic psoriasis treatment

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Preventive tuberculosis (TB) therapy before initiating MTX or IL‐17/IL‐23/IL‐12/23p40 inhibitors for latent tuberculosis infection (LTBI) is supported by indirect evidence of TB reactivations with TNF inhibitors. However, direct evidence for MTX or IL‐17/IL‐23/IL‐12/23p40 inhibitors is limited.
Christoph Zeyen   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy